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Abstract
Adeno-associated virus type 2 (AAV) is known to establish latency by preferential integration in human chromosome
19q13.42. The AAV non-structural protein Rep appears to target a site called AAVS1 by simultaneously binding to Rep-
binding sites (RBS) present on the AAV genome and within AAVS1. In the absence of Rep, as is the case with AAV vectors,
chromosomal integration is rare and random. For a genome-wide survey of wildtype AAV integration a linker-selection-
mediated (LSM)-PCR strategy was designed to retrieve AAV-chromosomal junctions. DNA sequence determination revealed
wildtype AAV integration sites scattered over the entire human genome. The bioinformatic analysis of these integration
sites compared to those of rep-deficient AAV vectors revealed a highly significant overrepresentation of integration events
near to consensus RBS. Integration hotspots included AAVS1 with 10% of total events. Novel hotspots near consensus RBS
were identified on chromosome 5p13.3 denoted AAVS2 and on chromsome 3p24.3 denoted AAVS3. AAVS2 displayed seven
independent junctions clustered within only 14 bp of a consensus RBS which proved to bind Rep in vitro similar to the RBS
in AAVS3. Expression of Rep in the presence of rep-deficient AAV vectors shifted targeting preferences from random
integration back to the neighbourhood of consensus RBS at hotspots and numerous additional sites in the human genome.
In summary, targeted AAV integration is not as specific for AAVS1 as previously assumed. Rather, Rep targets AAV to
integrate into open chromatin regions in the reach of various, consensus RBS homologues in the human genome.
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Introduction
The family of adeno-associated virus (AAV) represents defec-
tive, helper-dependent viruses that need to establish latency to
ensure persistence in their primate hosts [1]. Upon natural
infections in humans AAV genomes were shown to persist mainly
as episomes and integrated AAV genomes were rarely detected
[2]. The molecular mechanisms leading to integration have only
been characterized for AAV type 2 that prefers integration near a
site on human chromosome 19q13.42, called AAVS1 [3]. The
specificity of AAV integration is mediated by the large regulatory
AAV proteins, Rep78/68 [4]. During productive AAV replication
in the presence of either adeno- or herpesvirus as a helper virus,
Rep78/68 is required for AAV gene expression and DNA
replication. The AAV origins of DNA replication reside in the
145 bp inverted terminal repeats (ITRs) that flank the 4.7 kb
single-stranded AAV genome. Rep78 and/or Rep68 are expressed
from the AAV p5 promoter and were shown to bind to the Rep-
binding site (RBS) within the AAV-ITRs [5]. Rep unwinds the
DNA and introduces a single-strand nick at the adjacent terminal
resolution site (trs) [6]. The AAV-ITRs also serve as cis elements
for chromosomal integration [4]. A RBS homologue present in the
AAV p5 promoter was shown to mediate AAV integration in the
absence of the ITRs [7]. DNA sequences homologous to the RBS
and a nearby trs element were also found in AAVS1 [8,9] and, in
vitro, ternary complex formation of Rep68 with the AAV-ITR and
AAVS1 was shown [10]. A 33 bp sequence of AAVS1 spanning
the RBS and the trs element was sufficient to mediate AAV
integration in vivo [4,11]. AAV integrated at variable distances
from the RBS in AAVS1 and sequence rearrangements were
frequently found at AAV-chromosome junctions [8,9,12,13,
14,15]. Quantitative real-time PCR analysis of AAVS1-specific
AAV-2 integration within hours after AAV-2 infection and at
increasing MOIs showed that 10 to 20% of infected cells displayed
AAV integration within a 4 kb region of AAVS1 on chromosome
19q13.42 [16,17]. In AAV-infected and subsequently selected cell
clones up to 80% of AAVS1-specific integration had been
described before [18].
Although AAV has not been associated with disease in humans,
it is well established that AAV Rep78/68 induces DNA damage,
cell cycle arrest [19] and apoptosis [20]. In addition, AAV Rep
interferes with helper adenovirus- [21] herpes simplex virus
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therapy. As a rule, recombinant AAV vectors persist as non-
integrated, nuclear episomes. AAV vectors lack the integration
promoting rep gene and therefore only occasionally integrate into
the host cell genome. The preferred integration of wildtype AAV-2
in chromosome 19q13.42 is unique and is commonly viewed as a
specifically evolved virus-encoded targeting mechanism. Multiple
attempts were published that aim to exploit Rep-mediated
targeting specificity for chromosome 19q13.42 for the specific
integration of gene therapy vectors [23,24,25,26,27,28]. Yet
chromosome 19q13.42 is not the only target region. The presence
of alternative integration sites has long been postulated and in silico
analysis detected numerous consensus Rep-binding sites in the
human genome. Many of these bound Rep in vitro [29] but their in
vivo accessibility for AAV integration has not been explored so far.
From an evolutionary standpoint the assumption that AAV
latency is ensured by more than one target site or mechanism
appeared reasonable.
This study was designed to close the knowledge gap between
AAVS1-specific and assumedly non-AAVS1-specific wildtype
AAV integration and to compare the identified genomic sites to
those preferred upon AAV vector transduction. An open survey of
chromosomal integration preferences for wildtype AAV-2 was
conducted and complemented by the bioinformatic analysis of
genomic motifs and patterns in the genomic regions surrounding
the integration loci.
Results
General strategy of LSM-PCR
The genomic structure of latent AAV in infected cells is highly
variable. Wildtype AAV-2 was shown to integrate into the host cell
genome, as well as persist as extrachromosomal, nuclear episomes
[2,30]. In either case multicopy, concatemeric structures predom-
inate and often lead to unpredictable rearrangements involving the
145 bp inverted terminal repeats (ITRs). Therefore the retrieval of
AAV-chromosome junctions suffers from the inherent problem of
inefficient PCR reads through the hairpin ITR into the adjacent
chromosomal sequences. This leads to a predominance of
rearranged AAV genomes lacking chromosomal junctions in
previous PCR-based studies [31,32,33]. Furthermore, previously
cloned junctions often displayed unknown intervening sequences
of varying lengths between AAV and the identified chromosomal
sequence [12,15,16,27,34,35,36]. Therefore, unambiguous assign-
ment of the AAV-derived and chromosome-derived parts of
junctions requires sufficient DNA sequence lengths.
Several methods to identify virus-chromosome junctions have
been developed to study retrovirus integration, where generally a
single proviral copy per chromosomal site is found [37,38]. The
ultimate structure of the integrated long terminal repeat (LTR) is
generally predictable in a way that allows an integration-specific
PCR design. Linear amplification mediated (LAM)-PCR was
initially designed to retrieve rare retroviral vector integration sites
from small, clinical sample sizes [38]. We established a LAM-PCR
with AAV primers in the ‘‘D’’ element of the AAV-ITR, the
innermost and sole ITR region without internal inverse repetitions
(Figure 1A). Unfortunately, pure AAV sequences with rearranged
ITRs predominated, AAV-chromosome junctions were rare and
the chromosomal DNA part often too short for unambiguous
assignment to a unique genomic site. We then tested ligation-
mediated (LM)-PCR that had been employed for broad surveys of
lentivirus (HIV) or c-retrovirus (MLV) integrations [39,40,41].
LM-PCR relies on a first LTR-specific primer. A linker is ligated
to the first PCR strand that typically ends at the chosen restriction
site within the unknown chromosomal sequence. A primer
complementary to this linker ensures second strand synthesis and
retrovirus-chromosome junctions are amplified by using a
combination of retrovirus LTR-specific and linker-specific primer
sets.
For this study a variation of LM-PCR, named linker-selection-
mediated (LSM)-PCR was developed which enriched for bona fide
AAV-chromosome fusion sequences. The genomic DNA of AAV-
infected cells was cleaved with restriction enzymes that lead to
sufficiently sized DNA segments to allow unambiguous genomic
assignment of the chromosomal junction (Figure 1B). DNA
sequences were amplified with one primer for a unique AAV-
sequence, either of the p5 promoter or of the cap gene. The other
primer binds to the linker DNA attached to the unknown
chromosomal site. The structure of the linkers forces the PCR to
initiate within the AAV genome, thereby suppressing amplification
of chromosomal DNAs lacking integrated AAV. The use of non-
cut enzymes for AAV-2 DNA helped to circumvent the problem of
ligating linkers to episomal, non-integrated AAV DNA sequences.
To further enrich for AAV-chromosome junctions a biotin tag was
attached to the 59-end of the linker primer. Thus, chromosome-
derived PCR products could be enriched by streptavidin-mediated
magnetic bead selection. This lead to PCR products selected for
both, the presence of AAV and of an unknown chromosomal
DNA sequence.
AAV-2 integration sites
Using LSM-PCR a total of 1700 cloned PCR fragments were
screened for DNA inserts of a minimal fragment size (.500 bp) to
insure unambiguous detection of AAV-chromosome junctions.
Out of 350 DNA sequence runs a total of 129 unique junction sites
could be assigned to the human genome. Of these, 109 fulfilled the
criteria outlined in the methods for unambiguous assignment of a
single chromosomal site. Junctions were retrieved with non-cut
enzymes for AAV-2, PvuII or EcoRV or with DraI, which cuts
once in AAV-2 DNA outside of the region covered by the PCR. In
addition, 43 wildtype AAV-2 infected Hela-derived single cell
clones were generated of which eight harboured AAV-chromo-
some junctions that fulfilled the criteria outlined in the methods.
DNA sequence analysis revealed that AAV-2 wildtype integra-
tion sites were scattered over the entire human genome. The
Author Summary
This is the first unbiased genome-wide analysis of wildtype
AAV integration combined with a thorough bioinformatic
analysis of preferred genomic motifs and patterns in the
neighbourhood of the integration sites identified. The
preference of Rep-dependent AAV integration near
multiple consensus Rep-binding sites was lost in the case
of AAV vector integration in the absence of Rep
expression. Our findings challenge the commonly accept-
ed notion of site-specific AAV targeting to AAVS1 on
chromosome 19q13.42. Although AAVS1 contains a
canonical Rep-binding site, numerous additional sites
including the newly identified hotspots AAVS2 on
chromosome 5p13.3 and AAVS3 on chromosome 3p24.3
harbour functional Rep-binding sites suitable for AAV
integration. AAV vectors are quickly moving forward in the
clinic and Rep-dependent vector targeting strategies are
being actively pursued. Detailed information of AAV
wildtype versus recombinant AAV vector integration sites
and preferences are needed to evaluate the safety profile
of AAV vectors in gene therapy.
Wildtype AAV Integration Pattern
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one third of AAV integration sites were clustered at hotspots on
chr. 19q13.42, on chr. 5p13.3 and on chr. 3p24.3 (Figure 2B–D).
Infection with AAV in the absence of a helper virus leads to
transient, low Rep expression. Many previous AAV integration
studies used plasmid transfections of wildtype or vector AAV
constructs often in combination with a high-level Rep expression
construct. To evaluate whether high Rep expression influenced
the target site preference of AAV, the sequence data of previously
published transfection-based AAV integration sites [42] were
reevaluated with the more stringent criteria outlined in the
method. Of 157 DNA sequences retrieved after cotransfection of a
rep-expression construct and an AAV vector plasmid 47 junction
sequences fulfilled our criteria for unambiguous assignment of
AAV to a unique chromosomal site (Table 1).
Integration hotspots
For AAV wildtype 10% of all retrieved junctions were detected
at the hotspot on chr. 19q13.42 spread over a total of 33 kb
around AAVS1 (Figure 2B). Only one out of twelve chr. 19q13.42-
specific AAV junctions was located within the 4 kb region of
AAVS1, where a consensus Rep-binding site and an adjacent trs
site had been defined [4] The reevaluated distribution pattern of
junctions generated by transfection of AAV vector- and Rep
expression plasmids [42] was similar (Figure 2B). Latently AAV-
infected Detroit 6 cells [43,44] were analyzed as control. Using
cap-specific primers the junction was detected within AAVS1 at
nucleotide position 60,319,992. A second hotspot named AAVS2
was detected on the small arm of chr. 5p13.3 within an intergenic
region, where ten independent integration sites were detected
within 8 kb (Figure 2C). In seven of these junctions clustered
within 14 bp AAV had integrated directly into a consensus Rep
binding site. The reanalyzed chromosomal integrations from AAV
plasmid transfection [42] displayed a similar pattern with six
integrations within 16 bp of the consensus RBS (Figure 2C). The
third hotspot named AAVS3 was found on chr. 3p24.3
(Figure 2D). Out of 13 sites detected on chr. 3, three integrations
were clustered in a 8 kb region where a consensus Rep binding site
GAGT GAGT GAGT GAGC GAGC was detected on the
complement strand (Figure 2D).
Rep-binding affinity for RBS consensus sites in AAVS1,
-S2, and S3
To evaluate the binding affinities of Rep to the consensus RBS
of the hotspots on chr.5 and chr. 3 compared to the RBS of chr. 19
or within the AAV genome, double-stranded oligonucleotides
spanning the respective RBS regions (Figure 3) were submitted to
mobility shift assays (EMSA) with increasing amounts of purified
MBP-Rep78. Since it was previously shown that GAGG repeats
are deficient in binding to Rep [10,45], a mutated oligo derived
from the RBS of AAVS2 displaying GAGG GAGG GAGC
GAGG was used as a control. As an additional control, a random
oligonucleotide of similar length was used. As shown in figure 4,
the RBS of AAVS3 contained five instead of four GAGY repeats
and bound Rep with a two-fold higher affinity than the
oligonucleotide spanning the AAVS1 RBS and trs (Figure 4B).
The RBS of AAVS2 showed 76% of the Rep-binding affinity of
the AAVS1 sequence (Figure 4C). In contrast, the relative binding
affinity normalized to the AAVS1 sequence dropped to 13% with
the mutated AAVS2 oligonucleotide, which was in the range of the
random oligonucleotide (Figure 4C). These findings confirm the
importance of the GAGY repeats in Rep binding. As expected,
Rep78 displayed the highest affinities for oligonucleotides
spanning the A-stem of the AAV-ITR or the AAV p5–promoter
(Figure 4A, 4D). In summary, the newly discovered hotspots for
AAV integration, AAVS2 on chr. 5 and AAVS3 on chr. 3 display
RBS similarly proficient for Rep-binding as AAVS1.
Genomic features
To evaluate whether AAV-2 wildtype prefers specific motifs or
genomic features for chromosomal integration the detected
chromosomal junctions were compared to integration sites
described for infection of human cells with a rep-deleted AAV-2
based vector [46]. The published DNA sequence files were
reanalyzed using the criteria as outlined in the methods. This led
to 450 junctions that could be included as an AAV vector-specific
Figure 1. Linker-selection-mediated (LSM) PCR for cloning of
chromosomal AAV integration sites. (A) Genome structure of AAV-
2 with the rep and cap genes and their promoters flanked by inverted
terminal repeats (ITRs) at either end of the ssDNA genome. The hairpin-
structured ITRs contain internal repeat elements and complements
thereof, represented by small letters. The positions of the Rep-binding
sites (RBS) are represented by asterisks. (B) Schematic representation of
the LSM-PCR strategy for amplification of AAV-chromosomal junction
fragments. Wavy lines indicate chromosomal DNA. Linkers are displayed
by thick, grey lines, AAV-specific primers by small, horizontal arrows. For
restriction enzyme digestion indicated by vertical arrows either one of
the following enzymes were used: PvuII or EcoRV (non-cut for AAV-2) or
DraI (single-cut in AAV-2).
doi:10.1371/journal.ppat.1000985.g001
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genomic features was analyzed for rep-positive AAV wildtype and
for rep-deficient AAV vectors (Table 2). The data showed that the
integration frequency of AAV wildtype in genes was higher than
expected by chance (Table 2). The frequency was comparable to
that of rep-deficient AAV vectors, thus confirming the findings by
Miller et al. [46].
Chromatin state at AAV integration sites
To analyze the effect of epigenetic modifications on AAV
integration the association of integration sites with histone
modifications as markers for open or closed chromatin were
assessed by chromatin immunoprecipitation sequencing (ChIP-
Seq) analysis as outlined in the methods. Trimethylated lysine 27
of histone 3 (H3K27me3) is correlated with gene repression (closed
chromatin) [47], while methylation of lysine 4 in H3K4me3 and
H3K4me1 is indicative of promoter or enhancer regions (open
chromatin) [48]. As shown in table 2 the association of AAV
wildtype with open chromatin regions is significantly higher than
expected from random controls. Conversely, the respective
association with closed chromatin is significantly reduced. In
summary, AAV wildtype prefers integration into open chromatin
whereas closed chromatin was avoided.
Bioinformatic analysis of the AAV integration sites
A series of publications have shown that fused combinations of
two to four GAGC motifs bind to Rep78/68 of AAV-2
[4,49,50,51,52,53]. Moreover, in vitro ternary complex formation
of Rep68 with the AAV-2 ITR and AAVS1 of chr. 19q13.42 [10]
led to the concept of Rep acting as an adapter that targets AAV to
the human genome. Although only AAV-2 has been analyzed for
chromosomal integration so far, all known AAV serotypes
displayed various combinations of GAGC and/or GAGT motifs
in the ITR and the p5 promoter. An alignment of these AAV
elements to the integration hotspots AAVS1, AAVS2 and AAVS3
is displayed in Figure 3.
Based on these data we hypothesized that AAV-2 wildtype, due
to the presence of Rep, prefers integration at chromosomal sites in
closer proximity to consensus Rep binding sites than would be
expected from control sites. The hypothesis was tested with the
three sets of junctions derived from: 1. Infection with AAV-2
wildtype, 2. Cotransfection of plasmids coding for an AAV vector
and a constitutive Rep-expression cassette, and 3. Infection with
Rep-deficient AAV vectors (Table 1). The distances between any
one integration site and its nearest Rep-binding site were
determined in the human genome and compared to similarly
determined distances of individual control sites to the nearest Rep-
binding sites. Calculations were repeated using various combina-
tions of RBS as displayed in Figure 5.
The choice of randomly generated genomic control sites was
considered optimal for comparative analysis of the three sets of
data. Yet, a concern was the choice of restriction endonucleases for
the identification of the wildtype AAV-2 integration sites by LSM-
PCR. To control a bias introduced by a conceivable non-random
genomic distribution of the restriction sites, the average distance of
PvuII, EcoRV, or DraI-generated restriction sites to putative Rep-
binding sites was compared to the average distances of random
sites to Rep-binding sites. PvuII restriction sites were found to be
closer to Rep-binding sites than random control sites (Figure S1).
This was assumedly due to the high G+C content of the PvuII
recognition sequence and of the consensus Rep-binding sites. Both
EcoRV and DraI sites were found further apart from Rep-binding
sites in accordance with their high A+T content (Figure S1). To
circumvent any bias arising from the use of PvuII, the data set for
AAV wildtype infection was calculated against the data set of
random control sites as well as against the data sets for the
restriction site–related controls. Since not more than two thirds of
sites were generated with PvuII, the PvuII-related control sites
would at most underestimate the association to Rep-binding sites
and was therefore used as the most stringent control set. In
addition all calculations were also performed with the set of
random controls leading to similar findings (Figure S2).
Figure 2. Chromosomal distribution of AAV-2 integration sites. DNA of AAV-2 wildtype infected Hela cells was analyzed for viral integration
by the LSM-PCR-method. DNA sequence data from 117 cloned AAV-chromosome junctions were assigned to unique loci. (A) Distributions of
junctions on individual chromosomes are shown as percentage of the total 117. (B–D) AAV integration sites drawn to scale for chromosome 19 (B), 5
(C), and 3 (D). Shown are the chromosome ideograms and enlarged bands of hotspots found on chr. 19q13.42 (AAVS1) and chr. 5p13.3 (AAVS2). Solid
arrows represent sites detected upon wildtype AAV-2 infection. Open arrows represent junctions stemming from cotransfection of AAV vector- and
Rep-expression plasmids.
doi:10.1371/journal.ppat.1000985.g002
Table 1. Summary of data sets analysed in this study.
Author Reference Source of integration sites
Number of
junctions Aim of study
Drew et al. J Gen Virol, 2007 Cotransfection of neo-expressing AAV vector- and
rep expression plasmids in HeLa cells. Selection of
G418-resistent cell clones
47 (157) Characterization of Rep78-dependent
AAV-2 vector integration sites
Miller et al. J Virol, 2005 AAV-2 vector infection of human diploid fibroblasts,
no cell selection, analysis between
14–40 days p.i.
450 (1172) Integration site pattern of AAV-2 vector
integration (no rep)
Hu ¨ser et al. This study AAV-2 wt infection of HeLa cells, analysis at
4 days p.i.
109
a Integration site pattern of wildtype
AAV-2 integration
Hu ¨ser et al. This study AAV-2 wt infection of HeLa cells, expansion of single
cell clones, no selection, analysis at 3–4 weeks p.i.
8
a Integration site pattern of wildtype
AAV-2 integration
Numbers in brackets represent the total numbers of junctions published in the given reference.
aJunctions derived from AAV-2 wildtype infected cells four days p.i. and from those after clonal expansion were combined for statistical analyses.
doi:10.1371/journal.ppat.1000985.t001
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minimal Rep-binding site strikingly confirmed our hypothesis that
integration of wildtype AAV takes place close to Rep-binding sites
with very high significance (p ,0.0001). A comparable effect was
seen with the data set for AAV vectors in the presence of Rep
(p,0.001). Most importantly, the set of integration sites for AAV
vectors in the absence of Rep did not show any difference of
integration site preference compared to random control sites
(Figure 5A). With a frequency of 15,707 sites per human genome
the Rep binding motif GAGC GAGC occurs sufficiently frequent
to lead to a mean distance of around 50 kb to the next AAV
integration site in the presence of Rep. In the absence of Rep the
mean distance to AAV (vector) integration sites rises to around
130 kb (Figure 5A). To ensure that the presence of repetitive DNA
in the random controls did not lead to a bias in the analysis, an
independent control calculation was performed for AAV wt data
using AAV vector infection data as background. The high
significance level was maintained (data not shown). The
significance of the Rep-associated preferential integration near
GAGC GAGC sequences was further underlined by the results of
similar calculations for the putative Rep-binding motif GAGT
GAGC, where no such association was found. Only in the
presence of presumably large amounts of Rep (AAV vector
transfection, Rep+++) a small effect was seen (Figure 5B).
Obviously the GAGT GAGC motif is not sufficient to attract
Rep and the AAV genome for integration. When an additional
GAGC repeat is added (GAGY GAGC GAGC) the integration
preferences of AAV wildtype and Rep-expressing AAV vectors
shifted to closer proximity to Rep-binding sites (p,0.0001). This is
especially surprising since only 616 sites per human genome are
found for GAGY GAGC GAGC (Figure 5C). To allow more
potential Rep-binding site permutations, calculations were repeat-
ed with the consensus GAGC GAGC GAGC with one or two
random mismatches. This led to a significantly decreased mean
distance to AAV junctions in spite of the fact that up to 100-fold
more genomic hits were found for the motifs (Figure 5D; E). A
single nucleotide exchange in the GAGY GAGC GAGC motif
(Figure 5F, GAGY GAGC GAGA) on the other hand led to a
complete loss of association to AAV integration sites. This is
surprising in view of the reported in vitro binding of Rep to this
motif [45] and supports the assumption that the C at the 39 end of
the Rep binding motif is relevant for Rep-binding in vivo. Motifs
GCCC GAGT GAGC and GAGT GAGC ACGC are part of the
RBS in the viral p5 promoter. The individual motifs are found at
very low frequency (n=85, or n=82, respectively) in the human
genome, so that either no RBS was found in the same contig or the
distance to the next RBS was more than several thousands kb. For
these reasons we did not proceed with calculations for these motifs.
To further exclude the possibility that the calculated associations
with Rep binding sites were predominantly based on sequences
assigned to the hotspots AAVS1 and AAVS2, the significance of
the associations was re-evaluated with data sets omitted for the
hotspot sequences (Table 3). The robustness of the data becomes
evident by the fact that the highly significant association of AAV
junctions to motifs GAGC GAGC and GAGY GAGC GAGC is
maintained. In summary, AAV prefers integration sites in the
vicinity of consensus Rep-binding elements, most prominently on
chr. 19q13.42 (AAVS1), chr. 5p13.3 (AAVS2), and chr. 3p24.3
(AAVS3). But even in the absence of hotspots AAV still shows a
highly significant integration preference for Rep-binding motifs at
numerous additional sites in the human genome.
Discussion
This study represents the first genome-wide survey of wildtype
AAV-2 integration in the human genome combined with a
thorough bioinformatic analysis of the surrounding genome. We
show here that wildtype AAV-2 infection leads to preferential
integration in the vicinity of consensus Rep-binding sites (RBS) at
defined hotspots as well as at numerous additional genomic sites.
In contrast, AAV-2 vectors in the absence of Rep-expression
integrate without discernable preference for consensus Rep-
binding sites.
Hotspots of AAV integration
At the hotspot on chr. 19q13.42, up to 10% of all AAV
junctions were scattered over a region of 33 kb, mostly in
centromeric direction with regard to the previously defined core
4 kb AAVS1 site. AAV vectors in the absence of Rep expression
do not show any preference for chr. 19q13.42 [46]. The here
identified, novel hotspot AAVS2 on chr. 5p13.3 displayed roughly
8% of all junctions retrieved from wildtype AAV-2 infection and
23% of those retrieved from cotransfection of AAV vectors in the
presence of Rep distributed over a region of 14 kb. A cluster of 13
independent junctions was found within 14 bp of the AAVS2 RBS
that was shown to be similarly proficient in binding to Rep in vitro
as is the RBS of AAVS1 (Figure 4). The high in vivo integration
numbers may in part be due to the choice of HeLa as target cells.
These are hypertriploid with up to 12 copies of the p-arm of chr. 5
[54]. The extra gain of integrations within the described 8 kb
region is however unique for the AAVS2 site and not
accompanied by a parallel increase of integrations at additional
sites on the overrepresented p-arm of chr. 5, where 201 additional
Figure 3. Sequence alignment of Rep-binding sites. RBS
elements present in the ITR and the p5 promoter of all known AAV
serotypes are aligned and related to consensus RBS sites present at
chromosomal integration hotspots. Rep binding element GAGC is
d i s p l a y e di nb o l dl e t t e r s .B o t hG A G Ca n dG A G Te l e m e n t sa r e
highlighted in grey.
doi:10.1371/journal.ppat.1000985.g003
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GAGC repeats were counted. The only fourfold tetranucleotide
repeat on the chr.5 p-arm is found in AAVS2 (GAGT GAGT
GAGC GAGC; Figure 2C). In addition, junctions of rep-deficient
AAV vector were reported to be underrepresented on chr. 5 [46].
A major difference between the hotspots on chr. 5 and chr. 19
concerns the presence of genes. The junctions identified on chr. 19
span the region of the transcribed gene for protein phosphatase 1,
regulatory subunit 12C (PPP1R12C). The 8 kb AAVS2 sequence
identified on chr. 5p13.3 represents an intergenic region to the
best of current knowledge. It is well known that Rep expression
leads to extensive rearrangements of AAVS1 [18,55,56]. Appar-
ently, PPP1R12C is essential, since the majority of latently infected
cell lines display gene duplications [57] and simultaneous AAV
integrations in both alleles have never been reported. A currently
unresolved question concerns the presence of a terminal resolution
site (trs) next to the RBS of AAVS2 and AAVS3. In AAVS1 the
spatial configuration of RBS and trs resembles that of the AAV-
ITR. The trs element lies next to the RBS and serves as a nicking
site for Rep [4]. In AAVS2 and AAVS3 the nearest perfect trs
elements (59-GTTGG-39) are 400 and 500 bp away from the RBS,
which represents the mean statistical occurrence for this motif.
Unfortunately, the consensus nucleotide requirements for a
functional trs element are not defined well enough to conduct a
meaningful bioinformatic search. Therefore, the presence of
nicking sites next to the RBS in AAVS2 or AAVS3 remains open
at present.
Target site choice for AAV integration
Besides the identified integration hotspots numerous additional
chromosomal junction sites were found for integrated wildtype
AAV-2, scattered over the human genome. From the bioinfor-
matic calculations it appeared that the perfect tetranucleotide
repeat GAGC GAGC represented the minimal requirement for
Rep-dependent targeted integration, and GAGY GAGC GAGC
represents the optimized in vivo target sequence for wildtype AAV-
2. Hotspots AAVS1, AAVS2, and AAVS3 display this core
sequence fused to additional imperfect GAGY repeats. Other
AAV serotypes display RBS sequences with similar numbers of
GAGC and/or GAGT repeats, extended by additional imperfect
repeats. AAV5 Rep co-crystallised with the hairpin-structured
AAV5-ITR revealed that five Rep monomers bind to five
consensus tetranucleotide repeats of the RBS, each of which was
contacted by two Rep monomers from opposite faces of the DNA
[58]. AAV2-Rep78/68 was shown to simultaneously bind to the
RBS of the AAV-2 ITR and to that of AAVS1 [10]. Although it is
currently unknown whether other AAV serotypes integrate at all,
this is highly likely in view of the ability of both AAV-2 Rep and
the relatively distant AAV-5 Rep to multimerize and simulta-
neously bind to clustered GAGY repeats.
In the initial descriptions of AAVS1, site-specific nicking of the
trs by Rep bound to the adjacent RBS was viewed as preferred
entry site for AAV recombination [4]. Meanwhile the majority of
AAV integrations on chr. 19q13.42 were found many kb away
from the RBS-trs combination, and neither AAVS2 or AAVS3
display obvious trs homologues next to the RBS. Therefore
alternative explanations for RBS-dependent AAV integration
should be considered. The potential use of preexisting chromo-
somal breakage sites recalls a mechanism already proposed for the
integration of rep-deficient AAV vectors [34,59]. Alternative
integration concepts include the use of imperfect trs elements for
nicking as shown in vitro [4,60,61], or the ability of Rep78 to
induce DNA damage in vivo by single-strand nicking of cellular
Figure 4. Binding of MBP-Rep78 to Rep-binding sites of AAV-2 and of chromosomal integration hotspots. (A) to (C) Electrophoretic
mobility shift assays (EMSA) were performed with
32P-labeled double-stranded oligonucleotides in the presence of increasing amounts of affinity-
purified MBP-Rep78 as indicated above the autoradiograms. (D) Quantitative determination of the bound fractions of the different RBS and control
oligonucleotide probes as a function of the amount of MBP-Rep78 protein in the binding reaction. EMSA gels shown in (A) to (C) were subjected to
phosphorimager analysis to determine the relative amount of unbound and bound
32P-labeled oligonucleotides. The relative binding affinity was
calculated as follows: The highest amount of Rep used in this assay (1000 ng) bound 31% of the random oligonucleotide. The amount of Rep that
bound the same fraction of the other oligonucleotides was determined and normalized to the binding of the chr. 19 (AAVS1) oligonucleotide.
doi:10.1371/journal.ppat.1000985.g004
Table 2. Genomic features and chromatin state associated with AAV-2 wildtype- and AAV vector-derived integration sites.
Genomic feature
AAV wt infection %
of sites (n=117)
AAV vector infection
% of sites (n=450)
Random control
% of sites p-Value wt
a p-Value vector
a
RefSec genes 50.4 51.8 40.1 ,0.05 ,0.01
RefSec genes tss+/22 kb 6.8 5.6 2.9 ,0.05 ,0.01
Ens genes 51.1 51.3 40.7 ,0.05 ,0.0001
GenScan genes 83.8 74.0 69.5 ,0.001 ,0.05
Known genes 57.3 55.8 45.2 ,0.01 ,0.0001
Known genes exons 3.4 3.6 2.7 n.s. n.s.
CpG 0.9 1.6 0.7 n.s. ,0.05
CpG+/22 kb 7.7 6.4 4.1 n.s. ,0.05
Histone modification
H3K4me1 13.7 n.d. 7.5 ,0.05 n.d.
H3K4me3 6.8 n.d. 2.3 ,0.01 n.d.
H3K27me3 28.2 n.d. 42.2 ,0.01 n.d.
aP-values were determined in comparison to random controls, n.d. = not determined, p.0.05 were not considered statistically significant (n.s.).
doi:10.1371/journal.ppat.1000985.t002
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strand nicks occurs anywhere in accessible chromatin, even if the
nicking site is hundreds or thousands of bp apart from the RBS on
an extended DNA strand. HMGB1, an ubiquitous architectural
protein that serves as key component of the chromatin remodelling
complex may be of help [62]. Its long-known in vivo interaction
with Rep [63] may help remodel the chromatin to make it
accessible for nicking by Rep. Rep was also shown to contact other
key players of the nucleosome remodelling complex as compo-
nents of the transcription- or DNA replication machinery
Figure 5. Statistical analysis of distances of integration sites from human Rep-binding motifs. AAV integration sites of different data sets
were analyzed for the proximity to the next Rep binding sites. Calculations were performed with the following putative Rep binding sites: GAGC
GAGC (A); GAGT GAGC (B); GAGY GAGC GAGC (C); GAGC GAGC GAGC, one mismatch (D), or two mismatches allowed (E), and GAGY GAGC GAGA (F).
Average distances of integration sites from putative Rep binding sites are displayed as mean +/2 S.D. The levels of significance are marked by
asterisks. P-values .0.05 were not considered statistically significant. P-values ,0.01 were considered highly significant. For the analysis of wildtype
AAV integration data a PvuII-related control set was used in addition to the random control set.
doi:10.1371/journal.ppat.1000985.g005
Table 3. Neighbourhood analysis of wildtype AAV-2 integration sites and RBS motifs found outside of the hotspots on chr.
19q13.42 (AAVS1) and on chr. 5p13.3 (AAVS2).
RBS motif all integration sites (n=117) no chr.19q13.42 (n=106)
no chr.19q13.42 no chr.5p13.3
(n=96)
GAGC GAGC ,0.0001 ,0.0001 ,0.001
GAGY GAGC GAGC ,0.0001 ,0.001 ,0.01
GAGC GAGC GAGC (1 mismatch allowed) ,0.01 ,0.05 not significant
a
GAGC GAGC GAGC (2 mismatches allowed) ,0.001 ,0.01 ,0.05
Displayed are p-values calculated with the PvuII control set.
ap-values .0.05 were not considered statistically significant.
doi:10.1371/journal.ppat.1000985.t003
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chromatin for AAV integration. In summary, Rep with its
combined DNA-binding and endonuclease activity appears to
serve as a relatively imprecise targeting tool for AAV integration
preferably in open chromatin regions in the reach of consensus
Rep-binding sites prevalent in the human genome.
Implications for Rep-dependent targeting of AAV vector
integration
The early finding that Rep would mediate site-specific AAV
integration on chr. 19q13.42 had immediate implications for gene
therapy. A variety of concepts were devised to incorporate Rep as
an adapter to target AAV-ITR flanked transgenes to a specific site
[26,27,28,57,67]. In the majority of cases appropriate cell selection
or PCR for AAVS1 led to cells displaying the desired integration.
The reported high frequencies of integration into AAVS1 are
difficult to reconcile with our findings, unless the level of Rep
expression is considered to have an impact on target site choice.
Upon AAV infection Rep is only moderately expressed due to
autoregulation of the AAV p5 promoter. Rep-dependent AAV
vector transductions typically use strong heterologous promoters
that lead to high and sustained Rep expression levels. Increasing
Rep levels may increase the overall probability for integration
anywhere in the genome, including at hotspots. Under these
conditions AAVS1-specific integration will be detected more
readily. This appears however to come at the price of genomic
rearrangements in reach of alternative Rep-binding sites. There-
fore, it is plausible that in the absence of any selection AAV
integration into AAVS1 is typically unstable and difficult to detect.
In summary, Rep expression increases the probability for
integration next to one of several genomic hotspots. However, the
net genotoxic effect is unpredictable both with respect to the
integrity of the AAV integration locus itself and with respect to the
numerous additional sites where Rep binds and initiates
chromosomal damage. Therefore, the current concept of a
relatively precise site-specific targeting of AAV should be extended
to a concept of a relative preference for accessible chromatin
regions in the neighbourhood of any of the numerous consensus
Rep-binding sites. More recent approaches for site-specific vector
targeting try to exploit DNA sequence-specific zinc-finger
nucleases to target a genomic sequence of wish [68]. Although
zinc-finger nucleases are not free from off-target genotoxicity, at
least the genomic targeting site for the transgene can be more
precisely defined, a goal that appears to be inherently unachie-
vable using Rep as an adapter molecule.
Materials and Methods
Cells
Detroit 6 cells harbouring latent AAV-2 genomes and HeLa
cells were grown in Dulbecco’s modified Eagles’s medium (Gibco)
supplemented with 10% fetal calf serum, penicillin (100 U/ml),
and streptomycin (100 mg/ml).
AAV infection
Viral stocks of wildtype AAV-2 with infectious titers of 5610
9
i.u./ml were prepared on HeLa cells as described before [16]. For
the analysis of AAV integration sites 1.7610
6 HeLa cells were
seeded overnight on 10 cm diameter dishes and infected with
AAV-2 at a MOI of 500. Cells were harvested at 96 hours post
infection (p.i.) for the extraction of genomic DNA. The period of
cell growth after infection was minimized to reduce the chances of
selection of particular integration sites during cell proliferation.
Alternatively, AAV-infected HeLa cells were seeded to microtiter
plates at a dilution of 60 cells per plate and grown up as single-cell
clones without drug selection.
Plasmids
PlasmidpTAV2-0covers the AAV-2wildtypegenome(GenBank
accession number AF043303), pRVK the 4 kb fragment of the
AAVS1 locus on chromosome 19 (GenBank accession number
S51329), and pAAVS1-TR covers an AAV-ITR/AAVS1 junction
[16]. Plasmid pMBP-Rep78 encoding Rep78 fused to maltose-
binding protein (MBP) was described before [69].
Production and purification of MBP-Rep78 fusion protein
MBP-Rep78 encoding Rep78 fused to maltose-binding protein
was expressed und purified essentially as described [69]. Briefly,
E.coli strain BL21 transformed with pMBP-Rep78 was grown at
30uCt oa nO D 600 nm of 0.6 to 0.8. Production of MBP-Rep78 was
induced with 0.3 mM IPTG for 3 h at 30uC. Cells were harvested
by centrifugation and lysed by sonication for 2 min (30% duty
cycle) in lysis buffer of 50 mM phosphate pH 7.8, 300 mM NaCl,
1% (v/v) Triton X-100, 0.1 mM PMSF. Cell debris was removed
by centrifugation at 65006g for 20 min at 4uC. The supernatant
was adsorbed to amylose resin (New England Biolabs) in a batch
process and the resin was washed extensively (5 washes with about
100 volumes of the resin) with lysis buffer. The adsorbed proteins
were eluted with lysis buffer containing 10 mM maltose and
analyzed for purity by SDS-polyacrylamide gel electrophoresis.
Electophoretic mobility shift assays (EMSA)
Binding of MPB-Rep78 fusion protein to
32P- labeled double-
stranded oligonucleotide probes was detected by altered mobility
of the probes in nondenaturating polyacrylamide gels essentially as
described previously [70]. Briefly, oligonucleotides of 46–49 nt
length were end-labeled with T4 polynucleotide kinase and
annealed. EMSA reactions were performed for 20 min at 20uC
as follows: 0.015 pmol of labeled DNA substrate was incubated
with the indicated amounts of MBP or MBP-Rep78 in a binding
buffer containing 25 mM HEPES-KOH (pH 7.8), 10 mM MgCl2,
40 mM NaCl, 1 mM DTT, 2% glycerol, 12.5 mg/ml BSA, 0,01%
Nonidet P40 and 5 mg/ml salmon sperm DNA. The following
oligonucleotides were used:
AAV-ITR (nucleotide position 85–133): GCCTCAGTGAGC-
GAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCA;
AAV-ITR complementary strand: TGATGGAGTTGGCC-
ACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGC
Chr. 19q13.42 (AAVS1): TGGCGGCGGTTGGGGCT-
CGGCGCTCGCTCGCTCGCTGGGCGGGCGGGC
Chr19 (AAVS1) complementary strand: GCCCGCCCGC-
CCAGCGAGCGAGCGAGCGCCGAGCCCCAACCGCCGC-
CA
Chr. 5p13.3 (AAVS2): AGCTGGACCCCACGCTCGCT-
CACTCACTCTCCCCTCACCGCTTTGT
Chr. 5 (AAVS2) complementary strand: ACAAAGCGGT-
GAGGGGAGAGTGAGTGAGCGAGCGTGGGGTCCAGCT
Chr. 3p24.3 (AAVS3) GCTTCCCAAGGGGAATGAATGT-
GCGCTCGCTCACTCACTCACTCCTCAC
Chr.3 (AAVS3) complementary strand: GTGAGGAGTG-
AGTGAGTGAGCGAGCGCACATTCATTCCCCTTGGGA-
AGC
Chr. 5MUT (AAVS2 mutated): AGCTGGACCCCA-
CCCTCGCTCCCTCCCTCTCCCCTCACCGCTTTGT
Chr.5MUT (AAVS2 mutated), complementary strand: ACAA-
AGCGGTGAGGGGAGAGGGAGGGAGCGAGGGTGGGG-
TCCAGCT
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TAAGCCCGAGTGAGCACGCAGGGTCTCCATTTTG
AAV p5 complementary strand: CAAAATGGAGACCCT-
GCGTGCTCACTCGGGCTTAAATACCCAGCGTGA
random control: CAGAGCAGCAGCACAGACGCTAGCA-
GATCTCCTGCGACCGGAGATGTG
random control, complementary strand: CACATCTCC-
GGTCGCAGGAGATCTGCTAGCGTCTGTGCTGCTGCT-
CTG
Preparation of genomic DNA
Total genomic DNA was extracted by SDS/proteinase K
digestion followed by repeated phenol/chloroform extractions and
ethanol precipitation, as described before [71]. High molecular
weight DNA (2 mg) was digested with restriction enzymes that lead
to a mean genomic fragment size of around 4 kb and produce
blunt-ends ready for linker/adapter ligation. Non-cut enzymes for
AAV-2 DNA were preferred, PvuII, EcoRV. Additional junctions
were retrieved with DraI (one cut in AAV-2 wildtype DNA).
Digested genomic DNA was purified by repeated phenol-
chloroform extractions and precipitated with ethanol.
Linker-Selection-Mediated (LSM) PCR
A linker-based strategy described in [39,40] and outlined in
more detail in the manual of the GenomeWalker kit (Clontech)
was modified as outlined in Figure 1B. The following oligos were
used for linker construction: ‘‘Linkerlong’’ (59GTA ATA CGA
CTC ACT ATA CGG CAC GCG TGG TCG ACG GCC CGG
GCT GGT 39) and ‘‘linkershort’’ (59ACC AGC CC 39modifika-
tion: 29,39-dideoxyC). Equal amounts of ‘‘linkerlong’’ and
phosphorylated ‘‘linkershort’’ (100pmol each) were annealed and
ligated to restriction enzyme-digested genomic DNA.
PCR-primers: The linker-primers were ‘‘P linker outside’’ with
biotin attached to its 59 end (59-GTA ATA CGA CTC ACT ATA
CGG C; Tm=58.4uC) and ‘‘P linker nested’’ (59-ACT ATA CGG
CAC GCG TGG T; Tm=58.8uC). Two AAV-2-specific primer
sets were used. The first primer set covered the AAV p5 promoter:
‘‘AAV2p5’’ (59-TCA AAA TGG AGA CCC TGC GTG CTC A;
Tm=64.6uC, AAV-2, nt 293–269), primer ‘‘AAV2p5 nested’’ (59-
TAA ATA CCC AGC GTG ACC ACA TGG TG; Tm=64.8uC,
AAV-2, nt 260–235). The other primer set is located in the cap
gene region, as described before [2]: ‘‘CAPgsp1’’ (59-GTC TGT
TAA TGT GGA CTT TAC TGT GGA CAC; Tm=65.4uC,
AAV-2, nt 4320–4349) and ‘‘CAPgsp2’’ 59-GTG TAT TCA GAG
CCT CGC CCC AT; Tm=64.2uC, AAV-2 nt 4357–4379).
The PCR reaction contained 0.2 mM dNTPs, linker primer
and AAV specific primer (0.25 mM, each), 2.5 U proofreading
hot-start polymerase (Herculase) in reaction buffer, as provided by
the supplier (Stratagene). Of the preceding linker-ligation reaction
1–5 ml was added to a final volume of 50 ml. PCR conditions were
as follows: 3 min at 98uC, followed by 10 cycles of 40 sec at 98uC,
30 sec at 65uC, and 4 min at 72uC, followed by 20 cycles of 40 sec
at 98uC, 30 sec at 65uC, and 4 min + 10 sec per cycle at 72uC,
terminated by an extension period of 10 min at 72uC. Biotin-
labelled PCR products were further enriched on streptavidin-
labelled Dynabeads M-280, as outlined by the supplier (Invitro-
gen). Subsequent nested PCR used conditions identical to the first
round but with pairs of the nested PCR primers, as outlined above.
Finally, to add overhangs of multiple As, PCR products were
incubated with 1 U Taq polymerase (New England Biolabs).
Analysis of LSM PCR products
Products of LSM-PCR reactions were separated on agarose
gels. To ensure sufficient chromosomal fragment lengths, PCR
bands of a calculated minimal length (.500 bp) were excised and
purified by the QIAEX II Gel extraction kit (Qiagen, Hilden,
Germany). TOPO-TA cloning was performed as described [72].
Colonies were PCR-screened with the M13 forward (-20) and
reverse primer pair (0.4 mM, each) with 0.2 mM dNTP, 2 U Taq
polymerase (New England Biolabs) at the following conditions:
10 min at 94uC, followed by 30 cycles of 30 sec each at 94uC,
52uC, and 72uC, followed by 10 min at 72uC. Column-purified
PCR products were submitted to DNA sequencing using the
primer provided by the TOPO-TA cloning kit. DNA sequences
were run on a CEQ2000 genetic analysis system (Beckman) using
the CEQ Dye Terminator Cycle Sequencing Quick start kit
(Beckman) and the run method LFR-a. Cycling conditions were as
follows: 1 min at 96uC, followed by 30 cycles 20 sec at 96uC,
20 sec at 50uC and 4 min at 60uC.
Integration site determination
The genomic positions of AAV integration sites in the human
genome (assembly from March 2006, hg18) were determined using
the BLAT tool from the UCSC Genome Browser web site (http://
genome.ucsc.edu/cgi-bin/hgBlat) [73]. A match was defined as a
BLAT search result fulfilling all of the following criteria:
1. A human chromosome-derived part of the DNA sequence is at
least 100 bp in length and of 98% or higher homology to the
database.
2. A shorter chromosomal match is acceptable if it displays a
minimum of 25 bp of a contiguous DNA sequence match.
3. A part of the sequence allows assignment of AAV.
4. In the case of unassigned base pairs between the AAV and the
human part of the sequence, this sequence is no longer than
20 bp.
5. Sequences matching to multiple chromosomal regions (i.e.
repeat regions) were discarded in view of the inability to
unambiguously assign the surrounding genome for subsequent
bioinformatic analysis (see below).
6. Duplicate AAV-chromosomal fusion sequences (identical viral
and identical human DNA sequences) were counted only once.
In addition to the LSM-PCR derived sequences, the original
DNA sequence files of 157 chromosomal junctions [42] kindly
provided by Dr. G.W. Both, North Ride, Australia were
reanalyzed applying the above inclusion criteria. This led to 47
DNA sequences suitable for our analysis (Table 1). In their study,
HeLa cells had been cotransfected with plasmids for constitutive
RSV-promoter-driven Rep78 expression and for recombinant
AAV vectors expressing a SV40-promoter-driven neomycin gene
[42]. Furthermore, 1100 DNA sequences from a published
analysis of rep-deficient AAV vector integration sites in diploid
human cells [46] were reanalyzed. Since the PCR methods
employed in our study and in the one by Drew et al. [42] cannot
detect the matching left and right junction sites generated by one
AAV integration event, only one chromosomal junction was
analyzed per rescued provirus. The original DNA sequence files
(DU711025.1 to DU709854.1) of Miller et al. [46] were
downloaded from the Genome Survey Sequences (GSS) Database
of NCBI (http://www.ncbi.nlm.nih.gov/sites/entrez?db=nucgss)
and reanalyzed using the UCSC March 2006 human genome
build. The analysis led to a total of 450 junction sequences that
fulfilled all of the above inclusion criteria for bioinformatic
comparisons. For the subsequent data analysis we implemented
software in C++ using the software library SeqAn [74] and several
Python scripts.
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putative Rep binding sites
For different Rep binding motifs, we computed the average
distance of virus integration sites to the closest occurrences of Rep
binding motifs within the genome. We supposed that the observed
integration events were independent from each other and the
sample size was high enough for assuming the distance to be
normally distributed. To assess whether these distances differ
significantly from expectation, several background models were
generated:
(1) For the background model ‘‘random’’, we assumed that the
probabilities for the observation of virus integrations were
equally distributed among all conceivable positions in the
genome. A program was implemented that computed the
exact mean and standard deviation of this background
distribution.
(2) Since the integration site analysis required a suitable restriction
enzyme site in the neighbourhood of the integrated virus three
background-models for the restriction enzymes DraI, EcoRV
or PvuII were generated. These models served as a corrective
tool for an eventual bias of a non-uniform distribution of the
respective restriction enzyme sites in the genome. For each
AAV integration site observed, the distance to the closest
restrictionsite was determined individually.Then, 1000 control
sites per integration site were generated that displayed the same
distance to randomly chosen restriction sites.
The generation of both, the data analysis and the background
model was confined to those genomic contigs that contained at
least one Rep binding motif, since otherwise the distance to the
‘‘closest Rep binding motif’’ would not be defined. A given set of
AAV integration sites was considered to be significantly closer to
Rep binding motifs than expected by chance, if the significance
was calculated for all relevant background models. Data sets of
AAV vectors were analyzed with the ‘‘random’’ background
model. We applied a Z-test for determining statistical significances
for the distances of integration sites to Rep binding sites. For
comparing integration sites from AAV wildtype infection sites
against those from rep-deficient AAV vector infection we applied
the Student’s t-test.
Presence of genomic features
AAV integration sites were examined for the occurrence of
various genomic features using tables available in the UCSC
database. For the determination of significant divergences from
expectations, we compared the actual integration sites with a set of
100,000 randomly chosen control sites in the human genome
using a two-tailed binomial test.
Analysis of chromatin state
Chromatin immunoprecipitation sequencing (ChIP-Seq) data were
used to define the state of histone modifications in genomic regions of
AAV integration. H3K27me3 domains determined by Cuddapah
et al. were used as markers for closed chromatin (http://www.wip.
ncbi.nlm.nih.gov/projects/geo/query/acc.cgi?acc=GSM325898)
[75]. Regions enriched for H3K4 methylation (open chromatin)
were determined as follows: The raw ChIP-Seq reads by Robertson
et al. [76] (http://www.bcgsc.ca/data/histone-modification) were
mapped to the human genome using Bowtie [77], and peaks were
called using MACS [78]. H3K4me1/3 domains are then defined as
5 kb windows around the centers of the peaks.
Supporting Information
Figure S1 Distribution of restriction sites in relation to Rep
binding sites. (A) Cleavage sites of restriction enzymes used to
digest genomic DNA of wildtype AAV-2-infected Hela cells and
the numbers of occurrences per human genome are shown. (B)
The mean distances of restriction enzyme cleavage sites to Rep
binding sites were compared to those of random control sites to
Rep Binding Sites. Calculations are displayed for consensus RBS
that yielded significant proximity of integration sites to RBS as
displayed in Figure 5. P-values were , 0.00002 for all motifs.
Found at: doi:10.1371/journal.ppat.1000985.s001 (0.13 MB TIF)
Figure S2 Bioinformatic analysis of AAV-2 wildtype integration
sites. Distances of integration sites from Rep Binding Sites were
calculated and the z-score was assessed in relation to the following
control sites: (A) GAGC GAGC; (B) GAGT GAGC; (C) GAGY
GAGC GAGC; (D) GAGC GAGC GAGC one mismatch
allowed; (E) GAGC GAGC GAGC two mismatches allowed. In
order to analyze only the Rep-binding sites outside of integration
hotspot regions, sites within the hotspots of chr. 19 (AAVS1) and/
or chr. 5 (AAVS2) were omitted in separate calculations.
Found at: doi:10.1371/journal.ppat.1000985.s002 (0.25 MB TIF)
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